Global status of phenotypic pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates: an updated systematic review and meta-analysis

References

• WHO. https://www.who.int/publications/i/item/9789240037021.
   Google Scholar
• Alene KA, Wangdi K, Clements ACA. Impact of the COVID-19 pandemic on tuberculosis control: an overview. TropicalMed. 2020;5(3):123.
   Google Scholar
• Koch A, Cox H, Mizrahi V. Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment. Curr Opin Pharmacol. 2018;42:7–15.
   PubMed Web of Science ®Google Scholar
• MacNeil A, Glaziou P, Sismanidis C, et al. Global epidemiology of tuberculosis and progress toward meeting global targets—worldwide, 2018. MMWR Morb Mortal Wkly Rep. 2020;69(11):281–285.
   PubMed Web of Science ®Google Scholar
• Khoshnood S, Taki E, Sadeghifard N, et al. Mechanism of action, resistance, synergism, and clinical implications of delamanid against multidrug-resistant Mycobacterium tuberculosis. Front Microbiol. 2021;12:717045.
   Google Scholar
• Kazemian H, Heidari H, Kardan-Yamchi J, et al. Comparison of toxin-antitoxin expression among drug-susceptible and drug-resistant clinical isolates of Mycobacterium tuberculosis. Adv Respir Med. 2021;89(2):110–114.
   PubMed Web of Science ®Google Scholar
• Ye M, Yuan W, Molaeipour L, et al. Antibiotic heteroresistance in Mycobacterium tuberculosis isolates: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob. 2021;20(1):73.
   PubMed Web of Science ®Google Scholar
• Khoshnood S, Goudarzi M, Taki E, et al. Bedaquiline: current status and future perspectives. J Glob Antimicrob Resist. 2021;25:48–59.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Treatment of drug-susceptible tuberculosis: rapid communication. 2021.
   Google Scholar
• Njire M, Tan Y, Mugweru J, et al. Pyrazinamide resistance in Mycobacterium tuberculosis: review and update. Adv Med Sci. 2016;61(1):63–71.
   PubMed Web of Science ®Google Scholar
• Whitfield MG, Soeters HM, Warren RM, et al. A global perspective on pyrazinamide resistance: systematic review and meta-analysis. PLoS One. 2015;10(7):e0133869.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269, W64.
   PubMed Web of Science ®Google Scholar
• Lange C, van Leth F, Mitnick CD, et al. Time to revise WHO-recommended definitions of MDR-TB treatment outcomes. Lancet Respir Med. 2018;6(4):246–248.
   PubMed Web of Science ®Google Scholar
• Modesti PA, Reboldi G, Cappuccio FP, et al. Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis. PLoS One. 2016;11(1):e0147601.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
   PubMedGoogle Scholar
• Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. Int J Evid Based Healthc. 2018;16(4):195–203.
   PubMed Web of Science ®Google Scholar
• Ahmad B, Idrees M, Ahmad K, et al. Mutation analysis for detection of drug resistance in Mycobacterium tuberculosis isolates from Khyber Pakhtunkhwa, Pakistan. J Pak Med Assoc. 2017;67(11):1684–1688.
   PubMed Web of Science ®Google Scholar
• Ahmad N, Javaid A, Basit A, et al. Management and treatment outcomes of MDR-TB: results from a setting with high rates of drug resistance. Int J Tuberc Lung Dis. 2015;19(9):1109–1114.
   PubMed Web of Science ®Google Scholar
• Ahmad N, Javaid A, Sulaiman SA, et al. Resistance patterns, prevalence, and predictors of fluoroquinolones resistance in multidrug resistant tuberculosis patients. Braz J Infect Dis. 2016;20(1):41–47.
   PubMed Web of Science ®Google Scholar
• Aia P, Kal M, Lavu E, et al. The burden of drug-resistant tuberculosis in Papua New Guinea: results of a large population-based survey. PLoS One. 2016;11(3):e0149806.
   PubMed Web of Science ®Google Scholar
• Akbal AU, Durupinar B, Coban AY. Colorimetric methods for rapid determination of pyrazinamide resistance. Int J Mycobacteriol. 2020;9(3):274–280.
   PubMed Web of Science ®Google Scholar
• Al-Hayani AM, Kamel SA, Almudarra SS, et al. Drug resistance to anti-tuberculosis drugs: a cross-sectional study from Makkah, Saudi Arabia. Cureus. 2021;13(8):e17069.
   PubMed Web of Science ®Google Scholar
• Ali S, Khan MT, Sheed Khan A, et al. Prevalence of multi-drug resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa–a high tuberculosis endemic area of Pakistan. Pol J Microbiol. 2020;69(2):1–5.
   PubMed Web of Science ®Google Scholar
• Al-Mutairi NM, Ahmad S, Mokaddas EM. Molecular characterization of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) isolates identifies local transmission of infection in Kuwait, a country with a low incidence of TB and MDR-TB. Eur J Med Res. 2019;24(1):38.
   PubMed Web of Science ®Google Scholar
• Anastasakos V, Skouras V, Moschos C, et al. Patterns of drug resistance among patients with tuberculous pleural effusion in Greece. Int J Tuberc Lung Dis. 2017;21(3):309–313.
   PubMed Web of Science ®Google Scholar
• Andres S, Groschel MI, Hillemann D, et al. A diagnostic algorithm to investigate pyrazinamide and ethambutol resistance in Rifampin-resistant Mycobacterium tuberculosis isolates in a low-incidence setting. Antimicrob Agents Chemother. 2019;63(2):e01798-18.
   PubMed Web of Science ®Google Scholar
• Atif M, Bashir A, Ahmad N, et al. Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients. BMC Infect Dis. 2017;17(1):655.
   PubMedGoogle Scholar
• Aung WW, Ei PW, Nyunt WW, et al. Pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Myanmar. Antimicrob Agents Chemother. 2018;62(3):e01984-17.
   PubMed Web of Science ®Google Scholar
• Bai R, Chi S, Li X, et al. Genetic diversity and drug susceptibility patterns of the Mycobacterium tuberculosis complex in Yunnan, China. Biosci Rep. 2019;39(5):BSR20181746.
   Google Scholar
• Bitar I, Medvecky M, Amlerova J, et al. Frequency of mutations associated with resistance to first- and second-line drugs in multidrug-resistant Mycobacterium tuberculosis isolates. J Glob Antimicrob Resist. 2020;22:275–282.
   PubMed Web of Science ®Google Scholar
• Bouzouita I, Cabibbe AM, Trovato A, et al. Whole-genome sequencing of drug-resistant Mycobacterium tuberculosis strains, Tunisia, 2012-2016. Emerg Infect Dis. 2019;25(3):538–546.
   PubMed Web of Science ®Google Scholar
• Bwalya P, Yamaguchi T, Mulundu G, et al. Genotypic characterization of pyrazinamide resistance in Mycobacterium tuberculosis isolated from Lusaka, Zambia. Tuberculosis (Edinb). 2018;109:117–122.
   PubMed Web of Science ®Google Scholar
• Calderon RI, Velasquez GE, Becerra MC, et al. Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru. Int J Tuberc Lung Dis. 2017;21(8):894–901.
   PubMed Web of Science ®Google Scholar
• Cambau E, Viveiros M, Machado D, et al. Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study. J Antimicrob Chemother. 2015;70(3):686–696.
   PubMed Web of Science ®Google Scholar
• Cegielski JP, Kurbatova E, van der Walt M, et al. Multidrug-resistant tuberculosis treatment outcomes in relation to treatment and initial versus acquired second-line drug resistance. Clin Infect Dis. 2016;62(4):418–430.
   PubMed Web of Science ®Google Scholar
• Chaidir L, Ruesen C, Dutilh BE, et al. Use of whole-genome sequencing to predict Mycobacterium tuberculosis drug resistance in Indonesia. J Glob Antimicrob Resist. 2019;16:170–177.
   PubMed Web of Science ®Google Scholar
• Che Y, Bo D, Lin X, et al. Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China. BMC Infect Dis. 2021;21(1):1–8.
   PubMed Web of Science ®Google Scholar
• Chen X, He G, Wang S, et al. Evaluation of whole-genome sequence method to diagnose resistance of 13 anti-tuberculosis drugs and characterize resistance genes in clinical multi-drug resistance Mycobacterium tuberculosis isolates from China. Front Microbiol. 2019;10:1741.
   PubMedGoogle Scholar
• Chernyaeva E, Rotkevich M, Krasheninnikova K, et al. Genomic variations in drug resistant Mycobacterium tuberculosis strains collected from patients with different localization of infection. Antibiotics (Basel). 2020;10(1):27.
   PubMed Web of Science ®Google Scholar
• Chuang PH, Wu MH, Fan SY, et al. Population-based drug resistance surveillance of multidrug-resistant tuberculosis in Taiwan, 2007-2014. PLoS One. 2016;11(11):e0165222.
   PubMed Web of Science ®Google Scholar
• Daum LT, Konstantynovska OS, Solodiankin OS, et al. Characterization of novel Mycobacterium tuberculosis pncA gene mutations in clinical isolates from the Ukraine. Diagn Microbiol Infect Dis. 2019;93(4):334–338.
   PubMed Web of Science ®Google Scholar
• Diriba G, Kebede A, Tola HH, et al. Molecular characterization and drug resistance patterns of Mycobacterium tuberculosis complex in extrapulmonary tuberculosis patients in Addis Ababa, Ethiopia. PLoS One. 2020;15(12):e0243493.
   PubMed Web of Science ®Google Scholar
• Du Cros P, Khamraev A, Tigay Z, et al. Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan. ERJ Open Res. 2021;7(1):00537–2020.
   PubMedGoogle Scholar
• Dudley MZ, Sheen P, Gilman RH, et al. Detecting mutations in the Mycobacterium tuberculosis pyrazinamidase gene pncA to improve infection control and decrease drug resistance rates in human immunodeficiency virus coinfection. Am J Trop Med Hyg. 2016;95(6):1239–1246.
   PubMed Web of Science ®Google Scholar
• Ei PW, Mon AS, Htwe MM, et al. Pyrazinamide resistance and pncA mutations in drug resistant Mycobacterium tuberculosis clinical isolates from Myanmar. Tuberculosis (Edinb). 2020;125:102013.
   PubMed Web of Science ®Google Scholar
• Finci I, Albertini A, Merker M, et al. Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study. Lancet Microbe. 2022;3(9):e672–e82.
   PubMedGoogle Scholar
• Fregona G, Cosme LB, Moreira CMM, et al. Risk factors associated with multidrug-resistant tuberculosis in Espirito Santo. Brazil. Rev Saude Publica. 2017;51(0):41.
   Google Scholar
• Gallo J, Pinhata J, Simonsen V, et al. Prevalence, associated factors, outcomes and transmission of extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in São Paulo, Brazil: a cross-sectional study. Clin Microbiol Infect. 2018;24(8):889–895.
   PubMed Web of Science ®Google Scholar
• Gautam SS, Mac Aogain M, Cooley LA, et al. Molecular epidemiology of tuberculosis in Tasmania and genomic characterisation of its first known multi-drug resistant case. PLoS One. 2018;13(2):e0192351.
   PubMed Web of Science ®Google Scholar
• Genestet C, Hodille E, Berland JL, et al. Whole-genome sequencing in drug susceptibility testing of Mycobacterium tuberculosis in routine practice in Lyon, France. Int J Antimicrob Agents. 2020;55(4):105912.
   PubMed Web of Science ®Google Scholar
• Gu Y, Yu X, Jiang G, et al. Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates in a national referral center of China and its correlations with pncA, rpsA, and panD gene mutations. Diagn Microbiol Infect Dis. 2016;84(3):207–211.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Aroca JB, Ruiz P, Vaquero M, et al. Surveillance of drug-resistant tuberculosis in Spain (2001-2015). Microb Drug Resist. 2018;24(6):839–843.
   PubMed Web of Science ®Google Scholar
• Habous M, Elimam M, AlDabal L, et al. Pattern of primary tuberculosis drug resistance and associated risk factors at Dubai health authority in Dubai. Int J Mycobacteriol. 2020;9(4):391–396.
   PubMed Web of Science ®Google Scholar
• Hai HT, Vinh DN, Thu DD, et al. Comparison of the Mycobacterium tuberculosis molecular bacterial load assay, microscopy and GeneXpert versus liquid culture for viable bacterial load quantification before and after starting pulmonary tuberculosis treatment. Tuberculosis (Edinb). 2019;119:101864.
   PubMed Web of Science ®Google Scholar
• Hameed HA, Tan Y, Islam MM, et al. Detection of novel gene mutations associated with pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis clinical isolates in Southern China. Infect Drug Resist. 2020;13:217–227.
   PubMed Web of Science ®Google Scholar
• He G, Li Y, Chen X, et al. Prediction of treatment outcomes for multidrug-resistant tuberculosis by whole-genome sequencing. Int J Infect Dis. 2020;96:68–72.
   PubMed Web of Science ®Google Scholar
• He W, Tan Y, Liu C, et al. Drug-resistant characteristics, genetic diversity, and transmission dynamics of Rifampicin-resistant Mycobacterium tuberculosis in Hunan, China, revealed by whole-genome sequencing. Microbiol Spectr. 2022;10(1):e0154321.
   PubMed Web of Science ®Google Scholar
• Hu Y, Wu X, Luo J, et al. Detection of pyrazinamide resistance of Mycobacterium tuberculosis using nicotinamide as a surrogate. Clin Microbiol Infect. 2017;23(11):835–838.
   PubMed Web of Science ®Google Scholar
• Hu Y, Zheng X, Ning Z, et al. Impact of genotypic and phenotypic resistance to second-line anti-tuberculosis drugs on treatment outcomes in multidrug-resistant tuberculosis in China. Int J Mycobacteriol. 2016;5(Suppl. 1):S34–S35.
   PubMedGoogle Scholar
• Ignatyeva O, Balabanova Y, Nikolayevskyy V, et al. Resistance profile and risk factors of drug resistant tuberculosis in the Baltic countries. Tuberculosis (Edinb). 2015;95(5):581–588.
   PubMed Web of Science ®Google Scholar
• Iwamoto T, Murase Y, Yoshida S, et al. Overcoming the pitfalls of automatic interpretation of whole genome sequencing data by online tools for the prediction of pyrazinamide resistance in Mycobacterium tuberculosis. PLoS One. 2019;14(2):e0212798.
   PubMed Web of Science ®Google Scholar
• Jou R, Lee WT, Kulagina EV, et al. Redefining MDR-TB: comparison of Mycobacterium tuberculosis clinical isolates from Russia and Taiwan. Infect Genet Evol. 2019;72:141–146.
   PubMed Web of Science ®Google Scholar
• Juma SP, Maro A, Pholwat S, et al. Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania. BMC Infect Dis. 2019;19(1):129.
   PubMedGoogle Scholar
• Khan MT, Malik SI, Ali S, et al. Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan. BMC Infect Dis. 2019;19(1):116.
   PubMedGoogle Scholar
• Khan MT, Malik SI, Ali S, et al. Prevalence of pyrazinamide resistance in Khyber Pakhtunkhwa, Pakistan. Microb Drug Resist. 2018;24(9):1417–1421.
   PubMed Web of Science ®Google Scholar
• Khan MT, Rehaman AU, Junaid M, et al. Insight into novel clinical mutants of RpsA-S324F, E325K, and G341R of Mycobacterium tuberculosis associated with pyrazinamide resistance. Comput Struct Biotechnol J. 2018;16:379–387.
   PubMed Web of Science ®Google Scholar
• Ko DH, Lee EJ, Lee SK, et al. Application of next-generation sequencing to detect variants of drug-resistant Mycobacterium tuberculosis: genotype-phenotype correlation. Ann Clin Microbiol Antimicrob. 2019;18(1):2.
   PubMedGoogle Scholar
• Kuhlin J, Mansjö M, Wijkander M, et al. Genotypic resistance of pyrazinamide but not MIC is associated with longer time to sputum culture conversion in patients with multidrug-resistant tuberculosis. Clinical Infect Dis. 2021;73(9):e3511–e3517.
   PubMed Web of Science ®Google Scholar
• Kuo CY, Wang WH, Huang CH, et al. Resistance to first- and second-line antituberculosis drugs in Southern Taiwan: implications for empirical treatment. J Microbiol Immunol Infect. 2018;51(1):88–93.
   PubMedGoogle Scholar
• Li D, Hu Y, Werngren J, et al. Multicenter study of the emergence and genetic characteristics of pyrazinamide-resistant tuberculosis in China. Antimicrob Agents Chemother. 2016;60(9):5159–5166.
   PubMed Web of Science ®Google Scholar
• Li K, Yang Z, Gu J, et al. Characterization of pncA mutations and prediction of PZA resistance in Mycobacterium tuberculosis clinical isolates from Chongqing, China. Front Microbiol. 2020;11:594171.
   PubMedGoogle Scholar
• Lin S, Wei S, Zhao Y, et al. Genetic diversity and drug susceptibility profiles of multidrug-resistant tuberculosis strains in Southeast China. Infect Drug Resist. 2021;14:3979–3989.
   PubMedGoogle Scholar
• Liu D, Huang F, Zhang G, et al. Whole-genome sequencing for surveillance of tuberculosis drug resistance and determination of resistance level in China. Clin Microbiol Infect. 2022;28(5):731.
   Web of Science ®Google Scholar
• Liu W, Chen J, Shen Y, et al. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Hangzhou, China. Clin Microbiol Infect. 2018;24(9):1016.e1–1016.e5.
   PubMed Web of Science ®Google Scholar
• M Elhassan MA, Hemeg HA, Elmekki MA, et al. Burden of multidrug resistant Mycobacterium tuberculosis among new cases in Al-Madinah Al-Monawarah, Saudi Arabia. Infect Dis-Drug Target. 2017;17(1):14–23.
   PubMedGoogle Scholar
• Madrazo-Moya CF, Cancino-Muñoz I, Cuevas-Cordoba B, et al. Whole genomic sequencing as a tool for diagnosis of drug and multidrug-resistance tuberculosis in an endemic region in Mexico. PLoS One. 2019;14(6):e0213046.
   PubMed Web of Science ®Google Scholar
• Maningi NE, Daum LT, Rodriguez JD, et al. Improved detection by next-generation sequencing of pyrazinamide resistance in Mycobacterium tuberculosis isolates. J Clin Microbiol. 2015;53(12):3779–3783.
   PubMed Web of Science ®Google Scholar
• Maningi NE, Daum LT, Rodriguez JD, et al. Multi- and extensively drug resistant Mycobacterium tuberculosis in South Africa: a molecular analysis of historical isolates. J Clin Microbiol. 2018;56(5):e01214-17.
   PubMed Web of Science ®Google Scholar
• Mansjo M, Werngren J, Hoffner S. Characterization of pyrazinamide resistance in consecutive multidrug-resistant Mycobacterium tuberculosis isolates in Sweden between 2003 and 2015. Int J Mycobacteriol. 2017;6(2):156–161.
   PubMedGoogle Scholar
• Maslov DA, Zaĭchikova MV, Chernousova LN, et al. Resistance to pyrazinamide in Russian Mycobacterium tuberculosis isolates: pncA sequencing versus Bactec MGIT 960. Tuberculosis (Edinb). 2015;95(5):608–612.
   PubMed Web of Science ®Google Scholar
• Mehmood A, Khan MT, Kaushik AC, et al. Structural dynamics behind clinical mutants of PncA-Asp12Ala, Pro54Leu, and His57Pro of Mycobacterium tuberculosis associated with pyrazinamide resistance. Front Bioeng Biotechnol. 2019;7:404.
   PubMed Web of Science ®Google Scholar
• Meinzen C, Proano A, Gilman RH, et al. A quantitative adaptation of the Wayne test for pyrazinamide resistance. Tuberculosis (Edinb). 2016;99:41–46.
   PubMed Web of Science ®Google Scholar
• Mekonnen B, Mihret A, Getahun M, et al. Evaluation of the tuberculosis culture color plate test for rapid detection of drug susceptible and drug-resistant Mycobacterium tuberculosis in a resource-limited setting, Addis Ababa, Ethiopia. PLoS One. 2019;14(5):e0215679.
   PubMed Web of Science ®Google Scholar
• Modlin SJ, Marbach T, Werngren J, et al. Atypical genetic basis of pyrazinamide resistance in monoresistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2021;65(6):e01916-20.
   PubMed Web of Science ®Google Scholar
• Mok S, Roycroft E, Flanagan PR, et al. Overcoming the challenges of pyrazinamide susceptibility testing in clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother. 2021;65(8):e0261720.
   PubMed Web of Science ®Google Scholar
• Moradi J, Mohajeri P, Alvandi A, et al. Molecular identification of mutations associated with pyrazinamide-resistance in multidrug-resistant tuberculosis in eight provinces of Iran. JCDR. 2017;11(11):DC9–DC12.
   Google Scholar
• Naluyange R, Mboowa G, Komakech K, et al. High prevalence of phenotypic pyrazinamide resistance and its association with pncA gene mutations in Mycobacterium tuberculosis isolates from Uganda. PLoS One. 2020;15(5):e0232543.
   PubMed Web of Science ®Google Scholar
• Ng KKM, Yip PCW, Leung PKL. Prevalences of levofloxacin resistance and pncA mutation in isoniazid-resistant Mycobacterium tuberculosis in Hong Kong. Hong Kong Med J. 2021;27(6):421–427.
   PubMed Web of Science ®Google Scholar
• Pandey S, Lavu E, Congdon J, et al. Characterization of pncA mutations in multi-drug and pyrazinamide resistant Mycobacterium tuberculosis isolates cultured from Queensland migrants and Papua New Guinea residents. Tuberculosis (Edinb). 2018;111:109–113.
   PubMed Web of Science ®Google Scholar
• Pang Y, Wang Z, Zheng H, et al. Pyrazinamide resistance determined by liquid culture at low pH better correlates with genetic mutations in MDR tuberculosis isolates. J Microbiol Methods. 2015;119:142–144.
   PubMed Web of Science ®Google Scholar
• Pang Y, Zhang Z, Wang Y, et al. Genotyping and prevalence of pyrazinamide- and moxifloxacin-resistant tuberculosis in China, 2000 to 2010. Antimicrob Agents Chemother. 2017;61(2):e02170-16.
   PubMed Web of Science ®Google Scholar
• Pang Y, Zhu D, Zheng H, et al. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. BMC Infect Dis. 2017;17(1):1–8.
   PubMedGoogle Scholar
• Park J, Shin SY, Kim K, et al. Determining genotypic drug resistance by ion semiconductor sequencing with the ion AmpliSeq TB panel in multidrug-resistant Mycobacterium tuberculosis isolates. Ann Lab Med. 2018;38(4):316–323.
   PubMed Web of Science ®Google Scholar
• Park M, Lalvani A, Satta G, et al. Evaluating the clinical impact of routine whole genome sequencing in tuberculosis treatment decisions and the issue of isoniazid mono-resistance. BMC Infect Dis. 2022;22(1):349.
   PubMed Web of Science ®Google Scholar
• Park S, Jo KW, Shim TS. Treatment outcomes in multidrug-resistant tuberculosis according to pyrazinamide susceptibility. Int J Tuberc Lung Dis. 2020;24(2):233–239.
   PubMed Web of Science ®Google Scholar
• Piersimoni C, Mustazzolu A, Iacobino A, et al. Pyrazinamide susceptibility testing: proposed new standard with the BACTECTM MGITTM 960 system. Int J Tuberc Lung Dis. 2016;20(12):1677–1680.
   PubMed Web of Science ®Google Scholar
• Rahman A, Ferdous SS, Ahmed S, et al. Pyrazinamide susceptibility and pncA mutation profiles of Mycobacterium tuberculosis among multidrug-resistant tuberculosis patients in Bangladesh. Antimicrob Agents Chemother. 2017;61(9):e00511-17.
   PubMed Web of Science ®Google Scholar
• Ramirez-Busby SM, Rodwell TC, Fink L, et al. A multinational analysis of mutations and heterogeneity in PZase, RpsA, and PanD associated with pyrazinamide resistance in M/XDR Mycobacterium tuberculosis. Sci Rep. 2017;7(1):3790.
   PubMedGoogle Scholar
• Reena K, Kumar P, Shanthi V. Pyrazinamide drug resistance patterns in multi drug resistant Mycobacterium tuberculosis isolates from India. J Pure Appl Microbiol. 2016;10(3):2153–2164.
   Google Scholar
• Reena K, Shanthi V. Comparison of the modified Wayne’s test with the MGIT 960 for detection of pyrazinamide resistance in Mycobacterium tuberculosis isolates. Res J Pharma Biol Chem Sci. 2016;7(3):1884–1889.
   Google Scholar
• Rienthong S, Boonin C, Chaiyasirinrote B, et al. Evaluation of a novel line-probe assay for genotyping-based diagnosis of Mycobacterium tuberculosis in Thailand. Int J Tuberc Lung Dis. 2015;19(7):817–822.
   PubMed Web of Science ®Google Scholar
• Sengstake S, Bergval IL, Schuitema AR, et al. Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia. BMC Infect Dis. 2017;17(1):491.
   PubMedGoogle Scholar
• Shea J, Halse TA, Lapierre P, et al. Comprehensive whole-genome sequencing and reporting of drug resistance profiles on clinical cases of Mycobacterium tuberculosis in New York State. J Clin Microbiol. 2017;55(6):1871–1882.
   PubMed Web of Science ®Google Scholar
• Sheen P, Requena D, Gushiken E, et al. A multiple genome analysis of Mycobacterium tuberculosis reveals specific novel genes and mutations associated with pyrazinamide resistance. BMC Genomics. 2017;18(1):769.
   PubMedGoogle Scholar
• Shi J, Su R, Zheng D, et al. Pyrazinamide resistance and mutation patterns among multidrug-resistant Mycobacterium tuberculosis from Henan Province. Infect Drug Resist. 2020;13:2929–2941.
   PubMed Web of Science ®Google Scholar
• Silva Feliciano C, Rodrigues Placa J, Peronni K, et al. Evaluation of resistance acquisition during tuberculosis treatment using whole genome sequencing. Braz J Infect Dis. 2016;20(3):290–293.
   PubMed Web of Science ®Google Scholar
• Sodja E, Koren S, Toplak N, et al. Next-generation sequencing to characterise pyrazinamide resistance in Mycobacterium tuberculosis isolates from two Balkan countries. J Glob Antimicrob Resist. 2022;29:507–512.
   PubMed Web of Science ®Google Scholar
• Soetaert K, Ceyssens P-J, Boarbi S, et al. Retrospective evaluation of routine whole genome sequencing of Mycobacterium tuberculosis at the Belgian National Reference Center. Acta Clinica Belgica. 2022;77(5):853–860.
   PubMed Web of Science ®Google Scholar
• Spinato J, Boivin E, Belanger-Trudelle E, et al. Genotypic characterization of drug resistant Mycobacterium tuberculosis in Quebec, 2002-2012. BMC Microbiol. 2016;16(1):164.
   PubMedGoogle Scholar
• Suthum K, Samosornsuk W, Samosornsuk S. Characterization of katG, inhA, rpoB and pncA in Mycobacterium tuberculosis isolates from MDR-TB risk patients in Thailand. J Infect Dev Ctries. 2020;14(3):268–276.
   PubMed Web of Science ®Google Scholar
• Tagliani E, Hassan MO, Waberi Y, et al. Culture and next-generation sequencing-based drug susceptibility testing unveil high levels of drug-resistant-TB in Djibouti: results from the first national survey. Sci Rep. 2017;7(1):17672.
   PubMedGoogle Scholar
• Tam KK, Leung KS, Siu GK, et al. Direct detection of pyrazinamide resistance in Mycobacterium tuberculosis by use of pncA PCR sequencing. J Clin Microbiol. 2019;57(8):e00145-19.
   PubMed Web of Science ®Google Scholar
• Velasquez GE, Calderon RI, Mitnick CD, et al. Pyrazinamide resistance assays and two-month sputum culture status in patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2016;60(11):6766–6773.
   PubMed Web of Science ®Google Scholar
• Verdugo D, Fallows D, Ahuja S, et al. Epidemiologic correlates of pyrazinamide-resistant Mycobacterium tuberculosis in New York City. Antimicrob Agents Chemother. 2015;59(10):6140–6150.
   PubMed Web of Science ®Google Scholar
• Wang G, Jiang G, Jing W, et al. Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: a subsequent study of a national survey. J Infect. 2021;82(3):371–377.
   PubMed Web of Science ®Google Scholar
• Wang Z, Sun R, Mu C, et al. Characterization of fluoroquinolone-resistant and multidrug-resistant Mycobacterium tuberculosis isolates using whole-genome sequencing in Tianjin, China. Infect Drug Resist. 2022;15:1793–1803.
   PubMed Web of Science ®Google Scholar
• Werngren J, Alm E, Mansjö M. Non-pncA gene-mutated but pyrazinamide-resistant Mycobacterium tuberculosis: why is that? J Clin Microbiol. 2017;55(6):1920–1927.
   PubMed Web of Science ®Google Scholar
• Whitfield MG, Engelthaler DM, Allender C, et al. Comparative performance of genomic methods for the detection of pyrazinamide resistance and heteroresistance in Mycobacterium tuberculosis. J Clin Microbiol. 2022;60(1):e0190721.
   PubMed Web of Science ®Google Scholar
• Whitfield MG, Streicher EM, Dolby T, et al. Prevalence of pyrazinamide resistance across the spectrum of drug resistant phenotypes of Mycobacterium tuberculosis. Tuberculosis (Edinb). 2016;99:128–130.
   PubMed Web of Science ®Google Scholar
• Wollenberg KR, Desjardins CA, Zalutskaya A, et al. Whole-genome sequencing of Mycobacterium tuberculosis provides insight into the evolution and genetic composition of drug-resistant tuberculosis in Belarus. J Clin Microbiol. 2017;55(2):457–469.
   PubMed Web of Science ®Google Scholar
• Wu X, Lu W, Shao Y, et al. The indirect microscopic observation drug susceptibility assay demonstrated high concordance with the indirect MGIT method for pyrazinamide susceptibility testing. J Antimicrob Chemother. 2015;70(8):2295–2299.
   PubMed Web of Science ®Google Scholar
• Wu X, Lu W, Shao Y, et al. pncA gene mutations in reporting pyrazinamide resistance among the MDR-TB suspects. Infect Genet Evol. 2019;72:147–150.
   PubMed Web of Science ®Google Scholar
• Xia H, van den Hof S, Cobelens F, et al. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China. BMC Infect Dis. 2020;20(1):19.
   PubMed Web of Science ®Google Scholar
• Xia Q, Zhao L-L, Li F, et al. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Zhejiang, China. Antimicrob Agents Chemother. 2015;59(3):1690–1695.
   PubMed Web of Science ®Google Scholar
• Zenteno-Cuevas R, Fernandez E, Viveros D, et al. Characterization of polymorphisms associated with multidrug-resistant tuberculosis by whole genomic sequencing: a preliminary report from Mexico. Microb Drug Resist. 2020;26(7):732–740.
   PubMed Web of Science ®Google Scholar
• Zheng X, Ning Z, Drobniewski F, et al. pncA mutations are associated with slower sputum conversion during standard treatment of multidrug-resistant tuberculosis. Int J Antimicrob Agents. 2017;49(2):183–188.
   PubMed Web of Science ®Google Scholar
• Zhu J, Bao Z, Xie Y, et al. Additional drug resistance for Mycobacterium tuberculosis during turnaround time for drug-susceptibility testing in China: a multicenter observational cohort study. Int J Infect Dis. 2021;108:81–88.
   PubMed Web of Science ®Google Scholar
• Zurcher K, Ballif M, Fenner L, et al. Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study. Lancet Infect Dis. 2019;19(3):298–307.
   PubMed Web of Science ®Google Scholar
• Zignol M, Dara M, Dean AS, et al. Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data. Drug Resist Updat. 2013;16(6):108–115.
   PubMed Web of Science ®Google Scholar
• Zignol M, van Gemert W, Falzon D, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ. 2012;90(2):111–119D.
   PubMed Web of Science ®Google Scholar
• Sekiguchi J, Nakamura T, Miyoshi-Akiyama T, et al. Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis strains. J Clin Microbiol. 2007;45(9):2802–2807.
   PubMed Web of Science ®Google Scholar
• Whitfield MG, Marras SAE, Warren RM, et al. Rapid pyrazinamide drug susceptibility testing using a closed-tube PCR assay of the entire pncA gene. Sci Rep. 2020;10(1):4234.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO consolidated guidelines on tuberculosis: module 3: diagnosis-rapid diagnostics for tuberculosis detection: web annex 4: evidence synthesis and analysis. 2021.
   Google Scholar
• Shi W. Activity of pyrazinamide against Mycobacterium tuberculosis at neutral pH in PZA-S1 minimal medium. Antibiotics. 2021;10(8):909.
   Google Scholar
• World Health Organization. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. 2021.
   Google Scholar
• Kurbatova EV, Cavanaugh JS, Dalton T, et al. Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009. Clin Infect Dis. 2013;57(8):1081–1093.
   PubMed Web of Science ®Google Scholar
• Ramirez-Busby SM, Valafar F. Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother. 2015;59(9):5267–5277.
   PubMed Web of Science ®Google Scholar
• den Hertog AL, Sengstake S, Anthony RM. Pyrazinamide resistance in Mycobacterium tuberculosis fails to bite? Pathog Dis. 2015;73(6):ftv037.
   PubMed Web of Science ®Google Scholar
• Pecerska J, Kuhnert D, Meehan CJ, et al. Quantifying transmission fitness costs of multi-drug resistant tuberculosis. Epidemics. 2021;36:100471.
   PubMed Web of Science ®Google Scholar
• den Hertog AL, Sengstake S, Anthony RM. Pyrazinamide Resistance in Mycobacterium tuberculosis fails to bite? Pathogen Dis. 2015;73(6):ftv037.
   PubMed Web of Science ®Google Scholar